Article · 26 Oct 2026
Mini reviewPublished 27 Apr 2024
Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Focused Therapeutic Strategies for the Most Lethal Cancer
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Pancreatic Ductal Adenocarcinoma is among the most lethal cancers, characterized by limited treatment options and poor prognosis. Its hallmark resistance to conventional therapies necessitates the exploration of targeted therapeutic approaches. Recent advances have significantly deepened our understanding of the oncogenic pathways driving PDAC development and progression. This article reviews clinical and preclinical strategies targeting these pathways, highlighting promising avenues for treating this deadly cancer.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Cancer Clinical Trials.
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Cancer Clinical Trials
- SubjectOncology & Cancer
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “David Milar”
